Immunotherapy of type 1 diabetes

被引：11

作者：

Li, Li ^{[1
]}

Yi, Zuoan ^{[1
]}

Tisch, Roland ^{[1
]}

Wang, Bo ^{[1
]}

机构：

[1] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA

来源：

ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS | 2008年 / 56卷 / 04期

基金：

美国国家卫生研究院;

关键词：

antibody; antigen-specific; immunoregulatory T cells; tolerance;

D O I：

10.1007/s00005-008-0025-2

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Type 1 diabetes (T1D) is an autoimmune disease in which the insulin-producing beta cells are destroyed. Diabetic patients manage their hyperglycemia by daily insulin injections. However, insulin therapy is by no means a cure. Accordingly, a significant effort has been ongoing to develop immunotherapies that effectively prevent and/or treat T1D in the clinic. This review focuses on antigen- and antibody-based immunotherapies and discusses the respective strengths and weaknesses of these approaches.

引用

页码：227 / 236

页数：10

共 128 条

[91] Type 1 T regulatory cells [J].

Roncarolo, MG ;

Bacchetta, R ;

Bordignon, C ;

Narula, S ;

Levings, MK .

IMMUNOLOGICAL REVIEWS, 2001, 182 :68-79

[92] Naturally arising Foxp3-expressing CD25+ CD4+ regulatory T cells in immunological tolerance to self and non-self [J].

Sakaguchi, S .

NATURE IMMUNOLOGY, 2005, 6 (04) :345-352

[93] A RANDOMIZED TRIAL OF INTENSIVE INSULIN THERAPY IN NEWLY DIAGNOSED INSULIN-DEPENDENT DIABETES-MELLITUS [J].

SHAH, SC ;

MALONE, JI ;

SIMPSON, NE .

NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (09) :550-554

[94] Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes [J].

Sharif, S ;

Arreaza, GA ;

Zucker, P ;

Mi, QS ;

Sharif, S ;

Arreaza, GA ;

Zucker, P ;

Mi, QS ;

Sondhi, J ;

Naidenko, OV ;

Kronenberg, M ;

Koezuka, Y ;

Delovitch, TL ;

Gombert, JM ;

Leite-De-Moraes, M ;

Gouarin, C ;

Zhu, R ;

Hameg, A ;

Nakayama, T ;

Taniguchi, M ;

Lepault, F ;

Lehuen, A ;

Bach, JF ;

Herbelin, A .

NATURE MEDICINE, 2001, 7 (09) :1057-1062

[95] IMMUNOTHERAPY OF THE NONOBESE DIABETIC MOUSE - TREATMENT WITH AN ANTIBODY TO T-HELPER LYMPHOCYTES [J].

SHIZURU, JA ;

TAYLOREDWARDS, C ;

BANKS, BA ;

GREGORY, AK ;

FATHMAN, CG .

SCIENCE, 1988, 240 (4852) :659-662

[96] Murine antithymocyte globulin therapy alters disease progression in NOD mice by a time-dependent induction of immunoregulation [J].

Simon, Greg ;

Parker, Matthew ;

Ramiya, Vijayakumar ;

Wasserfall, Clive ;

Huang, Yanfei ;

Bresson, Damien ;

Schwartz, R. Fletcher ;

Campbell-Thompson, Martha ;

Tenace, Lauren ;

Brusko, Todd ;

Xue, Song ;

Scaria, Abraham ;

Lukason, Michael ;

Eisenbeis, Scott ;

Williams, John ;

Clare-Salzler, Michael ;

Schatz, Desmond ;

Kaplan, Bruce ;

von Herrath, Matthias ;

Womer, Karl ;

Atkinson, Mark A. .

DIABETES, 2008, 57 (02) :405-414

[97] Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects - A 16-month, randomized, comparative trial [J].

Skyler, JS ;

Weinstock, RS ;

Raskin, P ;

Yale, JF ;

Barrett, E ;

Gerich, JE ;

Gerstein, HC .

DIABETES CARE, 2005, 28 (07) :1630-1635

[98]

Skyler JS, 2002, NEW ENGL J MED, V346, P1685

[99]

Smith JA, 1998, J IMMUNOL, V160, P4841

[100] Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy [J].

Smith, JA ;

Tso, JY ;

Clark, MR ;

Cole, MS ;

Bluestone, JA .

JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (08) :1413-1422

← 4 5 6 7 8 9 10 11 12 13 →